| Phase I trial of oral S-1 combined with gemcitabine and cisplatin for advanced biliary tract cancer (KHBO1002). | |
| | |
MedLine Citation:
|
PMID: 22237958 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
PURPOSE: We aimed to determine the maximum-tolerated dose (MTD) and dose-limiting toxicities (DLTs) of the addition of S-1, an oral fluorouracil derivative, to gemcitabine and cisplatin combination therapy, which is the current standard treatment for advanced biliary tract cancer. METHODS: Patients with histologically or cytologically confirmed unresectable or recurrent biliary tract cancer were eligible for inclusion. The planned dosages of gemcitabine (mg/m(2))/cisplatin (mg/m(2))/S-1 (mg/m(2)/day) were as follows: level 0, 800/25/60; level 1, 1,000/25/60; and levels 2 and 3, 1,000/25/80. In each cycle, gemcitabine and cisplatin were intravenously administered on day 1 (or days 1 and 8 at level 3), and S-1 was orally administered twice daily on days 1-7 (or days 1-14 at level 3); this was repeated every 14 days (or 21 days at level 3). RESULTS: Seventeen patients were enrolled, and level 1 was chosen as the starting dose. Two of six patients developed DLTs (grade 4 neutropenia and grade 3 febrile neutropenia) at level 1, and the dose was escalated to level 2. DLTs (grade 3 rashes and grade 3 vasovagal reactions) occurred in two of six assessable patients at level 2; we then proceeded to level 3. The first three assessable patients enrolled at level 3 developed DLTs (two cases of grade 4 neutropenia, one of grade 4 leucopenia, two of grade 3 fatigue, one of grade 3 anorexia, and one of grade 3 febrile neutropenia) during their first cycle, and this dose was determined to be the MTD. Therefore, we selected level 2 as the recommended dose (RD) for a subsequent phase II study. CONCLUSIONS: We determined the RD of gemcitabine/cisplatin/S-1 combination therapy for advanced biliary tract cancer; we are proceeding to a phase II study to investigate the efficacy of this combination therapy for advanced biliary tract cancer. |
| | |
Authors:
|
Masashi Kanai; Etsuro Hatano; Syogo Kobayashi; Yutaka Fujiwara; Daisuke Sakai; Yuzo Kodama; Tetsuo Ajiki; Hiroaki Nagano; Tatsuya Ioka |
Related Documents
:
|
8084038 - Ischemia-reperfusion injury of the spinal cord: protective effect of the hydroxyl radic... 8458408 - Lack of effect of antioxidant therapy during renal ischemia and reperfusion in dogs. 21930888 - Population pharmacokinetics of fluconazole in critically ill patients receiving continu... 17607158 - Effects of the bradykinin b2 receptor antagonist icatibant on microvascular permeabilit... 10023498 - Psychosexual effects of three doses of testosterone cycling in normal men. 21409348 - Phase i clinical study of nmk36: a new pet tracer with the synthetic amino acid analogu... |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2012-1-12 |
Journal Detail:
|
Title: Cancer chemotherapy and pharmacology Volume: - ISSN: 1432-0843 ISO Abbreviation: - Publication Date: 2012 Jan |
Date Detail:
|
Created Date: 2012-1-12 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 7806519 Medline TA: Cancer Chemother Pharmacol Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Affiliation:
|
Outpatient Oncology Unit, Kyoto University Hospital, Kyoto, Japan, kanai@kuhp.kyoto-u.ac.jp. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Phase I and pharmacologic study of weekly amrubicin in patients with refractory or relapsed lung can...
Next Document: Ugt1a is required for the protective effect of selenium against irinotecan-induced toxicity.